Journey Medical financials
$6.49+0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $61.2M | $55.1M | $79.2M | $73.7M | $63.1M |
| Gross profit | $40.3M | $34.3M | $56.3M | $42.9M | $31.1M |
| Gross margin | 65.8% | 62.1% | 71.1% | 58.2% | 49.2% |
| Operating income | -$8.8M | -$14.7M | -$2.1M | -$27.5M | -$34.9M |
| Net income | -$11.4M | -$14.7M | -$3.9M | -$29.6M | -$44.0M |
| Net margin | −18.7% | −26.6% | −4.9% | −40.2% | −69.7% |
| Diluted EPS | $-0.47 | $-0.72 | $-0.21 | $-1.69 | $-4.32 |
| EBITDA | -$4.5M | -$11.3M | $4.8M | -$23.2M | -$32.3M |
| Operating cash flow | -$12.4M | -$9.1M | $5.2M | -$13.5M | -$2.2M |
| Free cash flow | -$12.4M | -$24.1M | $240.0K | -$33.5M | — |
| Diluted shares | 24.5M | 20.4M | 18.2M | 17.5M | 10.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $24.1M | $20.3M | $27.4M | $32.0M | $49.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $25.7M | $25.3M | $17.6M | $26.6M | $812.0K |
| Total assets | $94.6M | $80.2M | $76.8M | $105.2M | $97.3M |
| Total liabilities | $62.7M | $60.2M | $56.5M | $88.2M | $55.2M |
| Shareholders' equity | $31.9M | $20.1M | $20.4M | $17.0M | $42.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology